Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 39 EP103 | DOI: 10.1530/endoabs.39.EP103

BSPED2015 e-Posters Pituitary and growth (18 abstracts)

Does better adherence to GH treatment using jet rather than needle delivery translate into improved growth outcomes?

Maria Michaelidou 3 , Sue Whitten 2 , Priti Bajaj 2 & Helen Spoudeas 1


1London Centre for Paediatric Endocrinology, Great Ormond Street and University College London Hospitals, London, UK; 2Ferring Pharmaceuticals, London, UK; 3The University of Manchester Medical School, Manchester, UK.


Introduction: We wanted to assess whether our report of better adherence to GH therapy using jet (ZomaJet) rather than needle delivery in a large nationwide cohort, translated into better growth outcomes.

Aims and hypothesis: To retrospectively audit growth markers in our local split-site (GOSH/UCLH) cohort of children, starting GH using Zomajet between 01.01.2010 and 31.12.2012, for whom we had previous adherence (PDC) scores.

Methods: Of 75 local patients identified from the national cohort, 55 met the eligibility criteria for indication (GHD) and age (<16 years). Patients with PDC score >0.8 were considered adherent. Age and sex-SDS for height (HTSDS), IGF1 (IGF1SDS), and height velocity (HVSDS) were compared between and within adherent (n 33) and non-adherent (n 22) groups after 1 year and at end of assessment period with nonparametric statistics. Data is presented as median and range.

Results: There were no significant intergroup differences in baseline age, height, IGF1, mid-parental height (MPH) SDS, GH starting dose or duration. Eight patients in adherent and one patient in non-adherent groups switched to needle devices. Increments in HTSDS, HVSDS, and IGF1SDS at 1 year and end observation were similar between groups (P>0.05) with significant comparable gains in nine patients (six adherent) achieving adult HTSDS close to individual target MPHSDS (P<0.05). Significant longitudinal intragroup improvements occurred for adherent patients in HTSDS (n 27), IGF1SDS (n 14), and HVSDS (n 19) (P<0.05; see Table 1), but not for non-adherent patients (P>0.05).

Adherent patientsTreatment start, median (range)1 year of treatmentObservation period endP value (Friedman)
HTSDS−1.73 (−3.88 to 2.43)−0.99 (−3.62 to 0.98)−0.67 (−3.48 to 2.24)<0.01 S
HVSDS−1.92 (−6.70 to 4.68)1.21 (−2.53 to 6.52)1.08 (−5.03 to 11.11)0.03 S
IGF1SDS−2.70 (−4.10 to 1.30)−0.45 (−2.90 to 3.90)0.05 (−3.20 to 5.20)0.02 S

Conclusion: Improved adherence with Zomajet may translate into better height outcomes. This hypothesis will be explored in a larger local dataset comparing jet with needle devices.

Volume 39

43rd Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.